Clinical trials: Artery Disease, Peripheral
Peripheral Arterial Disease
Safety and Effectiveness Study of Eximo's B-Laser™ Atherectomy Device for PAD Treatment
The aim of the study is to assess the safety and efficacy of the use of the Eximo's B-Laser™ catheter in subjects affected with Peripheral Artery Disease (PAD) in lower extremity arteries.
- Trial name
- NCT02556255
- Testing
- B-Laser™ Atherectomy Catheter
- Where
- 2 sites in Poland
- Volunteers
- 57 people
- Sponsor
- Eximo Medical Ltd.
Peripheral Arterial Disease
Safety and Performance Study of the Shockwave Lithoplasty System
To study the safety and performance of the Shockwave Medical Lithoplasty System in subjects to demonstrate that the Shockwave device can safely and effectively deliver localized shockwave energy for balloon dilatation of…
- Trial name
- DISRUPT-PAD (NCT02071108)
- Testing
- Shockwave Lithoplasty System
- Where
- 3 sites in Austria, Germany and 1 more
- Volunteers
- 35 people
- Sponsor
- Shockwave Medical, Inc.
PAD
Effects of Heating on Exercise Pressor Reflex in Peripheral Artery Disease: Exercise Ability
The study objectives of this projects are to examine the hypothesis that the sympathetic and blood pressure responses to exercise will be attenuated during and after heat exposure in patients with peripheral artery disease, via…
- Trial name
- EPR (NCT03900832)
- Testing
- Without Heating, Warm Bath, Neutral Bath
- Where
- United States
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Milton S. Hershey Medical Center
CKD, PAD
lncRNAs as a Biomarker to Assess the Therapeutic Impact of Oral Absorbent ± Probiotics in CKD Patients With PAD
Participants with chronic kidney disease (CKD) are at a higher risk of developing atherosclerotic peripheral artery disease (PAD).
- Trial name
- NCT04788914
- Testing
- Active bamboo charcoal± probiotics
- Where
- Taiwan
- Volunteers
- 180 people
- Sponsor
- National Taiwan University Hospital
PAD
Endovascular Denervation Improves Limb Ischemia in Patients With Peripheral Artery Disease
Sympathetic overactivity partly promotes the development of peripheral artery disease which mainly leads to ischemia of the lower limbs.
- Trial name
- NCT04060797
- Testing
- endovascular denervation, PTA
- Where
- China
- Volunteers
- 38 people
- Sponsor
- Zhongda Hospital
Peripheral Artery Disease
Effects of Prolonged DAPT After Lower Extremity Percutaneous Transluminal Angioplasty (PTA) in Patients With LE-PAD
The objective of the present study was to evaluate the prognostic impact of prolonged dual antiplatelet therapy (DAPT) with acetylsalicylic acid plus clopidogrel on the incidence of major adverse cardiovascular events and major…
- Trial name
- LONGDAPTPAD (NCT02798913)
- Testing
- Short DAPT, Long DAPT
- Where
- Italy
- Volunteers
- 300 people
- Sponsor
- Federico II University
Myocardial Infarction, Diabetes Mellitus
Vorapaxar as an Add-On Antiplatelet Therapy in Patients With and Without Diabetes Mellitus
Dual antiplatelet therapy (DAPT) with aspirin and a P2Y12 receptor inhibitor, more frequently clopidogrel, represents the standard of care for the long-term secondary prevention of atherothrombotic events in patients with…
- Conditions
- Myocardial Infarction, Diabetes Mellitus, Peripheral Arterial Disease
- Trial name
- OPTIMUS-5 (NCT02548650)
- Testing
- Vorapaxar, Clopidogrel, Aspirin
- Where
- United States
- Volunteers
- 66 people
- Sponsor
- University of Florida
Peripheral Artery Disease
Exercise Testing in Peripheral Artery Disease Patients
The aim of this study was to evaluate exercise testing in case of patients suspected of Peripheral Artery Disease (PAD).
- Trial name
- ExercisePAD (NCT03186391)
- Testing
- Data collected
- Where
- France
- Volunteers
- 5,000 people
- Sponsor
- Rennes University Hospital
Anticoagulant Drugs, Antiplatelet Drug
Effect of Anticoagulant Drug Intervention on Postoperative MALE and MACE in Patients With PAD
Patients with PAD were grouped according to the combination of different anticoagulant and antiplate drugs. The type, dosage and duration of anticoagulant and antiplatelet drugs were recorded after operation.
- Conditions
- Anticoagulant Drugs, Antiplatelet Drug, Peripheral Arterial Disease
- Trial name
- NCT05852197
- Testing
- anticoagulant or antiplatelet drugs
- Where
- China
- Volunteers
- 6,000 people
- Sponsor
- First Affiliated Hospital of Zhejiang University
Peripheral Arterial Disease, Peripheral Vascular Disease
Safety Study of MultiGeneAngio in Patients With Chronic Critical Limb Ischemia
The purpose of this study is to evaluate the safety and activity of two doses of MultiGeneAngio, a cell therapy product produced from the patient's own cells, as potential treatment for patients with chronic critical limb…
- Conditions
- Peripheral Arterial Disease, Peripheral Vascular Disease, Critical Limb Ischemia
- Trial name
- NCT00956332
- Testing
- MultiGeneAngio
- Where
- 7 sites in Israel
- Volunteers
- 28 people
- Sponsor
- MultiGene Vascular Systems Ltd.
Cardiovascular Diseases, Peripheral Vascular Disease
The COPPER-B Trial
The purpose of the COPPER - B study is to assess the feasibility, safety, and initial efficacy of paclitaxel administration using the OPC for the prevention of restenosis in infrapopliteal de novo and restenotic lesions and…
- Conditions
- Cardiovascular Diseases, Peripheral Vascular Disease, Arterial Occlusive Diseases, Peripheral Arterial Disease
- Trial name
- COPPER-B (NCT02395744)
- Testing
- Paclitaxel administration using the OPC
- Where
- 4 sites in United States
- Volunteers
- 11 people
- Sponsor
- Horizons International Peripheral Group
Critical Limb Ischemia, Peripheral Arterial Disease
Safety and Efficacy Study of Autologous Concentrated Bone Marrow Aspirate (cBMA) for Critical Limb Ischemia (CLI)
This trial will evaluate the safety and efficacy of concentrated bone marrow aspirate (cBMA) to prevent or delay major amputation and/or death in subjects with critical limb ischemia (CLI) due to severe peripheral arterial…
- Conditions
- Critical Limb Ischemia, Peripheral Arterial Disease, Peripheral Vascular Disease
- Trial name
- MOBILE (NCT01049919)
- Testing
- Bone marrow concentration device
- Where
- 25 sites in United States
- Volunteers
- 153 people
- Sponsor
- Zimmer Biomet
Peripheral Arterial Disease
NanoCross BTK, a Prospective, Non-randomized, Multicenter, Controlled Trial Evaluating the Performance of the NanoCrossTM .014 Balloon Catheter in Infrapopliteal Lesions
The objective of this clinical evaluation is to evaluate the immediate and long-term (up to 12 months) outcome of NanoCrossTM balloon catheter (Covidien) in a prospective, non-randomised, controlled investigation for the…
- Trial name
- NCT01783600
- Testing
- NanoCross .014 balloon catheter
- Where
- 4 sites in Belgium
- Volunteers
- 100 people
- Sponsor
- Flanders Medical Research Program
Peripheral Vascular Disease
DiRectional AthErectomy + Drug CoAted BaLloon to Treat Long, CalcifIed FemoropopliTeal ArterY Lesions
This study is designed to collect information during a procedure that is routine care for treating a blockage in a blood vessel in the upper part of the participant's leg.
- Trial name
- REALITY (NCT02850107)
- Testing
- Medtronic HawkOne® or TurboHawk™, Medtronic IN.PACT® Admiral® DCB, Medtronic Spider™ Distal Protection Device (DPD)
- Where
- 7 sites in United States
- Volunteers
- 102 people
- Sponsor
- VIVA Physicians
Peripheral Artery Disease
Prospective, Post Market Surveillance Q3-registry (POLARIS)
This is a prospective, non-randomized post market surveillance registry designed to document the clinical Performance in Routine clinical practice of the POLARIS Peripheral Vascular Self Expanding Stent System
- Trial name
- Q3-Registry (NCT02307292)
- Testing
- POLARIS Peripheral Vascular Self Expanding Stent System
- Where
- Germany
- Volunteers
- 250 people
- Sponsor
- QualiMed Innovative Medizinprodukte GmbH
Critical Limb Ischemia (CLI)
Intra-arterial Infusion of Autologous Bone Marrow Mononuclear Cells in Non-diabetic Patients With Critical Limb Ischemia (CLI).
Phase II Clinical Trial, a prospective, multicenter, open, randomized, parallel-group controlled with three levels of dose. The hypothesis of the test we propose is that the mononuclear cells of bone marrow provide progenitor…
- Trial name
- NCT01408381
- Testing
- Intraarterial Infusion of Autologous Bone Marrow Mononuclear Cells
- Where
- 5 sites in Spain
- Volunteers
- 38 people
- Sponsor
- Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud
Peripheral Vascular Disease, Intermittent Claudication
Effect of Nike FuelBand on Exercise and Function in Claudicants; a Randomised Controlled Trial
This is a randomised controlled study of patients suffering from intermittent claudication (IC), to assess the impact of wearing a Nike FuelBand (NFB) on walking distances, exercise levels and quality of life.
- Trial name
- NCT01822457
- Testing
- Nike FuelBand (NFB)
- Where
- United Kingdom
- Volunteers
- 37 people
- Sponsor
- Imperial College London
Femoropopliteal Artery Lesions
Ranger™ and Ranger™ SL (OTW) DCB) in China
This clinical study is a prospective, non-randomized, multicenter study to demonstrate the acceptable safety and performance of angioplasty with the Ranger DCB in native femoropopliteal artery lesions.
- Trial name
- NCT02944071
- Testing
- Boston Scientific Ranger™ and Ranger™ SL Paclitaxel-Coated PTA Balloon Catheter
- Where
- 9 sites in China
- Volunteers
- 123 people
- Sponsor
- Boston Scientific Corporation
Peripheral Arterial Disease
Intermittent Mechanical Compression For Peripheral Arterial Disease
The study tests the use of a portable mechanical compression device (FM220, Flowmedic, USA) for the treatment of claudication and peripheral arterial disease.
- Trial name
- FM-S1 (NCT00855673)
- Testing
- Intermittent Mechanical Compression, Control
- Volunteers
- 30 people
- Sponsor
- Hospital Universitario Getafe
Peripheral Arterial Disease
Clinical Trial Investigating the Combination Therapy With Luminor DCB and iVolution Stent in TASC C and D Femoropopliteal Lesions
The T.I.N.T.I.N. study investigates the safety and efficacy of the combination therapy with the Luminor drug coated balloon (DCB) and the iVolution stent in the treatment of TASC C and D femoropopliteal lesions.
- Trial name
- TINTIN (NCT03347383)
- Testing
- Combination therapy DCB + stent
- Where
- 9 sites in Belgium
- Volunteers
- 100 people
- Sponsor
- ID3 Medical
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.